Novartis turns to algorithms developer Anumana to apply AI to cardio conditions

 
Novartis’s main offerings for cardiovascular disease are drugs prescribed as a response to symptoms. However, heart problems can develop years before signs appear and the pharmaceutical giant wants to find new approaches to these disorders. A new partnership aims to develop artificial…

Source: medcitynews.comRead more